Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8FIS

Structure of Bispecific CAP256V2LS-J3 Fab in complex with BG505 DS-SOSIP.664

8FIS の概要
エントリーDOI10.2210/pdb8fis/pdb
EMDBエントリー29209
分子名称Envelope glycoprotein gp41, 2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein gp120, ... (10 entities in total)
機能のキーワードcd4, hiv-1, sosip, vaccine, immune system, llama, v2 apex, therapeutic, viral protein, cap256, vrc26.25
由来する生物種Human immunodeficiency virus 1
詳細
タンパク質・核酸の鎖数10
化学式量合計381232.65
構造登録者
Gorman, J.,Kwong, P.D. (登録日: 2022-12-16, 公開日: 2023-02-01, 最終更新日: 2024-11-13)
主引用文献Zhang, B.,Gorman, J.,Kwon, Y.D.,Pegu, A.,Chao, C.W.,Liu, T.,Asokan, M.,Bender, M.F.,Bylund, T.,Damron, L.,Gollapudi, D.,Lei, P.,Li, Y.,Liu, C.,Louder, M.K.,McKee, K.,Olia, A.S.,Rawi, R.,Schon, A.,Wang, S.,Yang, E.S.,Yang, Y.,Carlton, K.,Doria-Rose, N.A.,Shapiro, L.,Seaman, M.S.,Mascola, J.R.,Kwong, P.D.
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency.
Mabs, 15:2165390-2165390, 2023
Cited by
PubMed Abstract: Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain of CAP256V2LS, an optimized version of CAP256-VRC26.25 currently under clinical evaluation, to the llama nanobody J3, which has broad CD4-binding site-directed neutralization. The J3-linked bispecific antibody exhibited improved breadth and potency over both J3 and CAP256V2LS, indicative of synergistic neutralization. The cryo-EM structure of the bispecific antibody in complex with a prefusion-closed Env trimer revealed simultaneous binding of J3 and CAP256V2LS. We further optimized the pharmacokinetics of the bispecific antibody by reducing the net positive charge of J3. The optimized bispecific antibody, which we named CAP256.J3LS, had a half-life similar to CAP256V2LS in human FcRn knock-in mice and exhibited suitable auto-reactivity, manufacturability, and biophysical risk. CAP256.J3LS neutralized over 97% of a multiclade 208-strain panel (geometric mean concentration for 80% inhibition (IC) 0.079 μg/ml) and 100% of a 100-virus clade C panel (geometric mean IC of 0.05 μg/ml), suggesting its anti-HIV utility especially in regions where clade C dominates.
PubMed: 36729903
DOI: 10.1080/19420862.2023.2165390
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (3.18 Å)
構造検証レポート
Validation report summary of 8fis
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon